BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Medilink Midlands - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Medilink Midlands
X-ORIGINAL-URL:https://staging.medilinkmidlands.com
X-WR-CALDESC:Events for Medilink Midlands
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20160327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20161030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20170326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20171029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20181028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20170303T080000
DTEND;TZID=Europe/London:20170303T170000
DTSTAMP:20260417T095454
CREATED:20171013T133314Z
LAST-MODIFIED:20171013T133314Z
UID:17659-1488528000-1488560400@staging.medilinkmidlands.com
SUMMARY:Accelerating Clinical Development from First-in-Human to Proof-of-Concept
DESCRIPTION:This seminar will describe how Quotient Clinical’s unique Enabled-First-in-Human® programs significantly reduce the time and cost required to transition to Proof of Concept.  The integration of real-time GMP manufacture and clinical testing minimises CMC investments and simplifies supply chains.  By enhancing the design and speed of early phase clinical programs\, the pressure on R&D budgets is reduced and critical decisions are made sooner. \nPresentation 1: First-in-Human to Proof-of-Concept – there is a better way! \nAlyson Connor\, Executive Director Exploratory Clinical Pharmacology \nA current perspective on the conduct of First-in-Human (FIH) programs in the UK will be shared\, highlighting the benefits of Quotient’s innovative approach.  Case studies will illustrate successes across a range of molecule classes and indications. \nPresentation 2: Adaptive CMC strategies for First in Human programs \nNikki Whitfield\, Vice President\, Pharmaceutical Sciences \nInsights into novel approaches for the development of fit-for-purpose FIH drug products to allow rapid entry into clinic will be described.  Proven strategies for a time- and cost-efficient transition\, within the FIH programme\, to a product suitable for downstream development will be presented. \nTo register your place\, please email Ciaran Flanagan. \nThis event is also taking place in Cambridge on Tuesday 21 February. To go to the event page\, please click here.
URL:https://staging.medilinkmidlands.com/event/accelerating-clinical-development-from-first-in-human-to-proof-of-concept-2/
LOCATION:Citadines Hotel\, Holborn\, London\, WC1V 6LF
END:VEVENT
END:VCALENDAR